TRACON Secures FDA Nod For Early-Stage Study In Soft-Tissue Cancer

The FDA has signed off TRACON Pharmaceuticals Inc's TCON initiation of a Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in sarcoma patients, including those who have not received prior therapy.
The Phase 1/2 trial will assess the safety and efficacy of YH001 and envafolimab in patients with the rare sarcoma subtypes of alveolar soft part sarcoma and chondrosarcoma.
Related: TRACON Pharma, Eucure Join Forces To Develop CTLA-4 Antibody For Oncology Indications.
Additionally, the safety and efficacy of YH001, envafolimab, and doxorubicin will be assessed in the more prevalent sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
YH001, an IgG1 antibody against CTLA-4, has shown enhanced antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro.
Price Action: TCON shares are up 0.50% at $2.02 on the last check Monday.